Moreover, spontaneous regression of melanoma with simultaneous onset of vitiligo has been reported [148] and metastatic melanoma responds to immune-stimulating agents, such as IFNs and IL-2 as well as the novel immune checkpoint inhibitors blocking cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and PD-1 [149–151]. Here, CTLA4 is linked to metastatic melanoma.